Pharmanutra

Regulatory Filings • Apr 15, 2020

Informazione Regolamentata n. 20106-16-2020		Data/Ora Ricezione 15 Aprile 2020 07:52:52	AIM -Italia/Mercato Alternativo del Capitale
Societa'	:	Pharmanutra S.p.A.
Identificativo Informazione Regolamentata	:	130761
Nome utilizzatore	:		PHARMANUTRAN02 - Lacorte Roberto
Tipologia	:	REGEM
Data/Ora Ricezione	:	15 Aprile 2020 07:52:52
Data/Ora Inizio Diffusione presunta	:	15 Aprile 2020 07:52:53
Oggetto	:		PR - PHN accordo con Pfizer 15_04_2020
Testo del comunicato

Vedi allegato.

PHARMANUTRA S.P.A.: PFIZER INVESTS IN SUCROSOMIAL® TECHNOLOGY

The innovative Sucrosomial® Magnesium developed by the PharmaNutra Group is one of the main ingredients of the new Multicentrum My Mag launched by Pfizer.

Pisa, 15th April 2020 - The pharmaceutical company PharmaNutra S.p.A. (Aim Italia -Ticker PHN), leader in the iron-based, nutritional supplements sector, reports on an important new scientific and commercial agreement for the innovative Sucrosomial® Technology patented by the Group.

Pfizer Consumer Healthcare Italy S.r.l., leader in the research, production and commercialisation of medicinal products, has chosen to include the Sucrosomial® Magnesium in the ingredients of its new Multicentrum My Mag. The product, available in Italy from April, will contain three different sources of magnesium including the exclusive formula developed and patented by Alesco srl, a PharmaNutra Group company specialised in the production and distribution of active principles.

This acknowledgement is especially important and prestigious for both the company and the innovative Sucrosomial® Technology, a unique, patented system that enables minerals to cross the gastric environment without obstacles; thus guaranteeing tolerability and high absorption levels. A patent that is already the base of several PharmaNutra brand products, like those in the SiderAL® line (Sucrosomial® Iron) and UltraMag® (Sucrosomial® Magnesium) itself which, in any case, will remain the market's sole product with a 100% Sucrosomial® formula.

The agreement with Pfizer was stipulated by PharmaNutra S.p.A. and Alesco Srl - the Group's two companies that own the trademark - and will enable the global pharma giant to use the "Sucrosomial®" brand and the Italian patent for the mineral-based, orodispersible formulas (No. 0001419366) limited to the Multicentrum My Mag product for the Italian market.

"The agreement we have signed with Pfizer to use our Sucrosomial® Magnesium in their new Multicentrum My Mag is a key step for our company growth and opens stimulating, new scenarios", declares the President Andrea Lacorte. "The fact that a company of Pfizer's stature has acknowledged the validity of our patent and has invested in a direct collaboration with the Group is not just very satisfying. It is also an important growth opportunity for our business, based - as this prestigious agreement confirms once again – on the high value of research".

PharmaNutra S.p.A.

Founded and led by the President Andrea Lacorte and Vice President Roberto Lacorte, PharmaNutra was established in 2003. It develops unique nutritional supplements and innovative nutritional devices, handling the entire production process, from proprietary raw materials to finished product. The efficacy of the products has been demonstrated with a wealth of scientific evidence, with 112 studies published involving more than 7000 subjects. The Group distributes and sells its products in Italy and abroad. In Italy, products are sold through a network of 140 Pharmaceutical Representatives serving doctors and also exclusively selling PharmaNutra products to pharmacies throughout Italy. Products are sold in over 50 countries abroad, through 34 partners selected from among the finest pharmaceutical companies. PharmaNutra leads the market in the production of iron-based nutritional supplements under the SiderAL® brand, where it boasts a number of important patents on Sucrosomial® technology. Over the years, the Group has developed a precise strategy for the management and production of intellectual property, founded on the integrated management of all the various elements: proprietary raw materials, patents, brands and clinical evidence.

www.pharmanutra.it

For Information:

PharmaNutra S.p.A.	Nomad CFO SIM S.p.A.	Press Office Spriano Communication & Partners
Via Delle Lenze, 216/b 56122 Pisa Tel. +39 050 7846500 investorrelation@pharmanutra.it	Via dell'Annunciata, 23/4 20121 Milan Tel. +39 02 303431 ecm@cfosim.com	Via Santa Radegonda, 16 20121 Milan Tel. +39 02 83635708
Internal Press Office press@calabughi.com		Matteo Russo mrusso@sprianocommunication.com Cristina Tronconi

ctronconi@sprianocommunication.com